WASHINGTON, D.C. (June 6, 2022) – The Association for Accessible Medicines (AAM) announced the appointment of Giuseppe Randazzo as Vice President of Sciences and Regulatory Affairs, effective June 6. In that role, Giuseppe will advise and support association leadership with respect to key developments and relationships within the industry’s regulatory landscape and work with members to create and communicate regulatory priorities that facilitate patient access to more affordable generic and biosimilar medicines.
Prior to joining AAM, Giuseppe worked on Novartis’ regulatory affairs team, where he collaborated in multiple regulatory policy arenas including drug and policy development, UFA negotiations, and trade association relations. Before Novartis, Giuseppe spent nearly 15 years at the Food and Drug Administration (FDA), where he was most recently an Office Director leading a team of 220 employees under the FDA’s Center for Drug Evaluation and Research. During his time at FDA, Giuseppe also worked in the Office of New Drugs, the Office of Compliance, and helped stand up the Office of Product Quality in coordination with the Office of Generic Drugs.
Giuseppe holds a B.A. in Chemistry and Physical Science Education from The Pennsylvania State University and an M.S. in Regulatory Science from The Johns Hopkins University.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.